SEC Form 4 · accession 0001415889-17-001484
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Caribou Biosciences, Inc.
10% Owner
Period of report
Sep 13, 2017
Accepted (ET)
Sep 13, 2017 · 6:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 13, 2017 | S$0 | 1,048,846 | — | D | 4,545,000 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transfer of stock relates to the Exclusive License Agreement, by and among Caribou Biosciences, Inc., The Regents of the University of California, and the University of Vienna, dated April 16, 2013.
- F2This Form 4 is filed on behalf of (i) Caribou Therapeutics Holdco, LLC, the direct holder of the shares, and (ii) Caribou Biosciences, Inc. Caribou Therapeutics Holdco, LLC is a wholly-owned subsidiary of Caribou Biosciences, Inc., and thus Caribou Biosciences, Inc. may be deemed to share voting and dispositive power with respect to the shares held by Caribou Therapeutics Holdco, LLC. Caribou Biosciences, Inc. disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, if any.